Hepatitis C Trial, Recruiting (NCT03135886)

Hepatitis C Trial, Recruiting NCT03135886 Sponsor: Columbia University Condition: Hepatitis C

Printed from Voxsanity (voxsanity.com.au) — NCT03135886 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hepatitis C

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The site (clinic or healthcare location) must see at least 150 different patients per year
The site must be able and willing to keep track of how many patients are offered HIV and/or Hepatitis C (HCV) tests, how many complete those tests, how many are referred for care if they test positive, and how many connect with care within 30 days of a positive result
The site must be able and willing to share general information about patients (such as gender and race/ethnicity as group totals, not individual details) and information about how HIV/HCV testing is paid for
Key staff members at the site must be willing to take part in surveys, interviews, and coaching sessions throughout the study

Who may not be able to join:

Sites where more than half of their patients already received an HIV or Hepatitis C test in the past 6 months will not be eligible
Sites may be removed from the trial if the lead researcher decides it is necessary (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lisa Metsch, PhD, Columbia University

Phone: 786-703-9819

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03135886

Sponsor: Columbia University

Phase: Not Applicable

Status: Recruiting

Condition: Hepatitis C

Trial contact: 786-703-9819

More information: https://clinicaltrials.gov/study/NCT03135886

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The site (clinic or healthcare location) must see at least 150 different patients per year
The site must be able and willing to keep track of how many patients are offered HIV and/or Hepatitis C (HCV) tests, how many complete those tests, how many are referred for care if they test positive, and how many connect with care within 30 days of a positive result
The site must be able and willing to share general information about patients (such as gender and race/ethnicity as group totals, not individual details) and information about how HIV/HCV testing is paid for
Key staff members at the site must be willing to take part in surveys, interviews, and coaching sessions throughout the study

Who may not be able to join:

Sites where more than half of their patients already received an HIV or Hepatitis C test in the past 6 months will not be eligible
Sites may be removed from the trial if the lead researcher decides it is necessary (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Columbia University

Registry

ClinicalTrials.gov

Start date

12 June 2017

Est. completion

31 January 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of OTP patients HIV tested at 6 months post intervention or control, while controlling for HIV testing during the baseline period (T1)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov